title: Tretinoin emollient cream for photodamaged skin: results of 48-week, multicenter, double-blind studies.
abstract: BACKGROUND
  The ability of topical tretinoin to improve certain signs of skin photodamage has been shown previously.
  
  
  OBJECTIVE
  Our purpose was to assess the effectiveness of tretinoin emollient cream in maintaining or further improving photodamaged skin during extended use.
  
  
  METHODS
  Photodamaged subjects who completed 24 weeks of once-daily use of tretinoin emollient cream 0.05% (n = 149) or 0.01% (n = 149) continued to use the same strength formulation in a 24-week double-blind extension.
  
  
  RESULTS
  Maintenance of improvement or continued reduction in signs of photodamage was noted in both investigators' and subjects' evaluations of the 0.05% and 0.01% preparations; these results were confirmed by skin replica analyses. Cutaneous side effects were less common during the extension study than during the first 24 weeks of therapy.
  
  
  CONCLUSIONS
  Both strengths of tretinoin emollient cream (0.05% and 0.01%) appeared safe and effective in the treatment of photodamaged skin during a 48-week treatment period.
authors.affiliation: Dermatopharmacology Study Center, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Olsen
authors.forename: H I
authors.initials: HI
authors.lastname: Katz
authors.forename: N
authors.initials: N
authors.lastname: Levine
authors.forename: T P
authors.initials: TP
authors.lastname: Nigra
authors.forename: P E
authors.initials: PE
authors.lastname: Pochi
authors.forename: R C
authors.initials: RC
authors.lastname: Savin
authors.forename: J
authors.initials: J
authors.lastname: Shupack
authors.forename: G D
authors.initials: GD
authors.lastname: Weinstein
authors.forename: L
authors.initials: L
authors.lastname: Lufrano
authors.forename: B H
authors.initials: BH
authors.lastname: Perry
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009824:Ointments; D012867:Skin / Q000033:anatomy & histology / Q000187:drug effects / Q000528:radiation effects; D015595:Skin Aging / Q000187:drug effects* / Q000528:radiation effects*; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D014466:Ultraviolet Rays / Q000009:adverse effects*
chemical_list: D007641:Keratolytic Agents; D009824:Ointments; D014212:Tretinoin